Recently added

Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts

Pronsati, Nancee; Green, Gerald; Liu, Geoffrey; Bauer, Todd; Goto, Yasushi; FELIP, ENRIQUETA (Elsevier, 2025-08)

A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1)

Cercek, Andrea; Starling, Naureen; Chen, Eric; Salvatore, Lisa; BACHET, Jean-Baptiste; Capdevila Castillon, Jaume (Elsevier, 2025-06)

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy

steuer, conor; Su, Wu-Chou; Nishio, Makoto; Hayashi, Hidetoshi; Johnson, Melissa; Kim, Dong-Wan; FELIP, ENRIQUETA (American Society of Clinical Oncology, 2025-09-01)

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial

Chandana, Sreenivasa R; Kiss, Igor; Melisi, Davide; Macarulla, Teresa; DE LA FOUCHARDIERE, CHRISTELLE; Pazo-Cid, Roberto A. (Elsevier, 2025-08)

Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas

Wermke, Martin; KUBOKI, YASUTOSHI; Sanmamed, Miguel F.; Alese, Olatunji B.; Gambardella, Valentina; FELIP, ENRIQUETA (American Society of Clinical Oncology, 2025-09-20)

Scientia. Department of Health Digital Information Depot

VHIO - Articles científics: Recent submissions

Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts

A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1)

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial

Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas

Scientia. Department of Health Digital Information Depot

VHIO - Articles científics: Recent submissions

Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts ﻿

A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1) ﻿

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy ﻿

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial ﻿

Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas ﻿

Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts

A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1)

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial

Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas